[go: up one dir, main page]

HUE057713T2 - A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek - Google Patents

A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek

Info

Publication number
HUE057713T2
HUE057713T2 HUE17193256A HUE17193256A HUE057713T2 HU E057713 T2 HUE057713 T2 HU E057713T2 HU E17193256 A HUE17193256 A HU E17193256A HU E17193256 A HUE17193256 A HU E17193256A HU E057713 T2 HUE057713 T2 HU E057713T2
Authority
HU
Hungary
Prior art keywords
spa
variants
protein
compositions
methods
Prior art date
Application number
HUE17193256A
Other languages
English (en)
Inventor
Olaf Schneewind
Alice Cheng
Dominique Missiakas
Hwan Kim
Original Assignee
Univ Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chicago filed Critical Univ Chicago
Publication of HUE057713T2 publication Critical patent/HUE057713T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HUE17193256A 2009-04-03 2010-04-05 A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek HUE057713T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16643209P 2009-04-03 2009-04-03
US23795609P 2009-08-28 2009-08-28
US28799609P 2009-12-18 2009-12-18

Publications (1)

Publication Number Publication Date
HUE057713T2 true HUE057713T2 (hu) 2022-05-28

Family

ID=43429726

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17193256A HUE057713T2 (hu) 2009-04-03 2010-04-05 A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek
HUE10797468A HUE026855T2 (hu) 2009-04-03 2010-04-05 Protein A (SPA) variánsokkal kapcsolatos készítmények és módszer

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE10797468A HUE026855T2 (hu) 2009-04-03 2010-04-05 Protein A (SPA) variánsokkal kapcsolatos készítmények és módszer

Country Status (22)

Country Link
US (1) US9567379B2 (hu)
EP (3) EP3002293A1 (hu)
JP (1) JP5789250B2 (hu)
KR (2) KR20170102039A (hu)
CN (1) CN102612523B (hu)
AU (1) AU2010271116B2 (hu)
BR (1) BRPI1010307B1 (hu)
CA (1) CA2757543C (hu)
CY (1) CY1123052T1 (hu)
DK (2) DK2414387T3 (hu)
ES (2) ES2563646T3 (hu)
HK (1) HK1162533A1 (hu)
HR (2) HRP20160274T1 (hu)
HU (2) HUE057713T2 (hu)
LT (1) LT3281947T (hu)
PL (2) PL2414387T3 (hu)
PT (2) PT2414387E (hu)
SG (1) SG174968A1 (hu)
SI (2) SI3281947T1 (hu)
SM (2) SMT202000246T1 (hu)
WO (1) WO2011005341A2 (hu)
ZA (1) ZA201107702B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CN102612523B (zh) 2009-04-03 2016-01-20 芝加哥大学 与蛋白a(spa)变体相关的组合物和方法
WO2011028492A2 (en) * 2009-08-24 2011-03-10 The Regents Of The University Of California Sortase a inhibitors
KR101893225B1 (ko) * 2010-03-24 2018-08-29 가부시키가이샤 가네카 면역 글로불린에 특이적으로 결합하는 단백질 및 면역 글로불린 결합성의 친화성 리간드
EP2555794A4 (en) * 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
KR20130093084A (ko) 2010-07-02 2013-08-21 더 유니버시티 오브 시카고 단백질 A(SpA) 변이체와 관련된 조성물 및 방법
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012034067A1 (en) * 2010-09-09 2012-03-15 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
PT3590949T (pt) 2010-10-01 2022-08-02 Modernatx Inc Ácidos ribonucleicos contendo n1-metilpseudouracilos e suas utilizações
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
JP5812303B2 (ja) * 2011-06-03 2015-11-11 国立研究開発法人産業技術総合研究所 酸性域での親和性が低下したプロテインa変異型タンパク質及び抗体捕捉剤
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
SG11201402666WA (en) 2011-12-16 2014-10-30 Moderna Therapeutics Inc Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013142349A1 (en) * 2012-03-23 2013-09-26 University Of Chicago Compositions and methods related to staphylococcal sbi
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP2847329A4 (en) 2012-04-02 2016-08-10 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF CYTOPLASMA AND CYTOSCELETTE PROTEINS
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9701738B2 (en) 2012-04-26 2017-07-11 The University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during Staphylococcus aureus disease
CN104768572B (zh) * 2012-04-26 2021-08-24 芝加哥大学 葡萄球菌凝固酶抗原及其使用方法
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US20160074497A1 (en) * 2013-05-03 2016-03-17 The University Of Chicago Staphylococcus live cell vaccines
CN105377880B (zh) * 2013-07-10 2020-08-07 通用电气医疗集团生物工艺研发股份公司 突变的免疫球蛋白结合多肽
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
CN103540588B (zh) * 2013-10-08 2016-06-08 杨波 一种基因工程改造的免疫球蛋白-亲和蛋白
WO2015085463A1 (zh) * 2013-12-09 2015-06-18 重庆原伦生物科技有限公司 金黄色葡萄球菌SpA5突变体、包含该突变体的组合物及制备方法和应用
US10328140B2 (en) * 2014-03-26 2019-06-25 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
WO2016095832A1 (en) * 2014-12-18 2016-06-23 The University Of Hong Kong Immunotherapeutic targets against staphylococcus aureus
CN106188251B (zh) * 2015-05-06 2020-07-31 上海迈泰君奥生物技术有限公司 一种免疫球蛋白结合蛋白突变体及其用途
JP7117244B2 (ja) 2016-02-12 2022-08-12 ザ・ユニバーシティ・オブ・シカゴ 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
EP3969031A4 (en) 2019-05-14 2023-10-25 The University of Chicago METHODS AND COMPOSITIONS COMPRISING STAPHYLOCOCCUS PROTEIN A (SPA) VARIANTS
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CA3155424A1 (en) * 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
CN112898387B (zh) * 2021-03-24 2023-04-28 成都欧林生物科技股份有限公司 一种重组金黄色葡萄球菌疫苗抗原蛋白的纯化方法
CN114605508B (zh) * 2022-05-11 2022-07-29 北京达成生物科技有限公司 能够结合于抗体分子Fc区域的抗体结合蛋白及其应用
CN116218751A (zh) * 2022-10-20 2023-06-06 昆明医科大学 一种金黄色葡萄球菌SdrC蛋白基因敲除的方法
KR102650818B1 (ko) * 2024-01-04 2024-03-27 한국콜마주식회사 황색포도상구균 단백질 a에 대한 항체를 포함하는 피부 진단용 키트

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
GB1499035A (en) 1975-04-10 1978-01-25 Ts Nii Gematologii I Perelivan Antistaphylococcus human immune globulin and method of preparing same
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4327082A (en) 1979-07-12 1982-04-27 Adcock-Ingram Laboratories Limited Mastitis vaccination
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4338298A (en) 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US5151350A (en) 1982-10-27 1992-09-29 Repligen Corporation Cloned genes encoding recombinant protein a
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5189015A (en) 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US5320951A (en) 1987-06-01 1994-06-14 Hoeoek Magnus Fibronectin binding protein as well as its preparation
FR2619122B1 (fr) 1987-08-03 1990-03-09 Pasteur Institut Procede d'obtention de polyosides capsulaires de staphylocoques, polyosides obtenus, applications de ces polyosides et souches pour la mise en oeuvre du procede
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5258494A (en) * 1988-04-08 1993-11-02 Stryker Corporation Osteogenic proteins
US5858652A (en) 1988-08-30 1999-01-12 Abbott Laboratories Detection and amplification of target nucleic acid sequences
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
NZ251621A (en) 1992-03-26 1996-04-26 Microcarb Inc Polyclonal antibodies to shiga-like toxins
WO1994000977A1 (en) 1992-07-07 1994-01-20 Japan Tobacco Inc. Method of transforming monocotyledon
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
EP0652965A1 (en) 1992-07-27 1995-05-17 Pioneer Hi-Bred International, Inc. An improved method of agrobacterium-mediated transformation of cultured soybean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
WO1994006830A1 (en) 1992-09-21 1994-03-31 Alfa-Laval Agri International Aktiebolag Fibrinogen binding protein
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5846709A (en) 1993-06-15 1998-12-08 Imclone Systems Incorporated Chemical process for amplifying and detecting nucleic acid sequences
FR2708288B1 (fr) 1993-07-26 1995-09-01 Bio Merieux Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé.
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
JPH10500862A (ja) 1994-05-28 1998-01-27 テプネル・メディカル・リミテッド 核酸のコピーの産生
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5942391A (en) 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5935825A (en) 1994-11-18 1999-08-10 Shimadzu Corporation Process and reagent for amplifying nucleic acid sequences
US5548066A (en) 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US6770278B1 (en) 1994-12-02 2004-08-03 Central Biomedia, Inc. Methods of making and using immunoglobulin (Ig) compositions
US5843650A (en) 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
WO1997014800A1 (en) 1995-10-16 1997-04-24 Smithkline Beecham Plc Novel saliva binding protein
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US6833253B2 (en) 1996-01-05 2004-12-21 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and polypeptides
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
FR2746398B1 (fr) 1996-03-21 1998-04-30 Bio Merieux Anticorps specifique de staphylococcus aureaus, et utilisations
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
WO1997043314A2 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US6013763A (en) * 1996-06-04 2000-01-11 Genentech, Inc. Peptide variants of protein A
US5939291A (en) 1996-06-14 1999-08-17 Sarnoff Corporation Microfluidic method for nucleic acid amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5849546A (en) 1996-09-13 1998-12-15 Epicentre Technologies Corporation Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
AU734443C (en) 1996-10-23 2005-04-14 Wyeth Vaccines
US5849497A (en) 1997-04-03 1998-12-15 The Research Foundation Of State University Of New York Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US5916776A (en) 1997-08-27 1999-06-29 Sarnoff Corporation Amplification method for a polynucleotide
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5932451A (en) 1997-11-19 1999-08-03 Incyte Pharmaceuticals, Inc. Method for unbiased mRNA amplification
JP4486748B2 (ja) 1997-11-26 2010-06-23 インヒビテツクス,インコーポレイテツド 黄色ブドウ球菌由来の細胞外マトリックス結合タンパク質
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
WO2000002523A2 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
ATE422368T1 (de) 1998-08-31 2009-02-15 Inhibitex Inc Multikomponenten impfstoffe gegen staphylococcus aureus
AU762978B2 (en) 1998-08-31 2003-07-10 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
MXPA01002120A (es) 1998-08-31 2003-03-27 Trinity College Dublin Polipeptidos y polinucleotidos de estafilococo negativo a coagulasa.
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
EP1109911A4 (en) 1998-09-01 2005-04-27 Human Genome Sciences Inc STAPHYLOCOCCUS AUREUS GENES AND ASSOCIATED POLYPEPTIDES
WO2000015238A1 (en) 1998-09-14 2000-03-23 Nabi COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP1173466A4 (en) 1999-04-28 2002-10-16 Trinity College Dublin METHOD FOR AVOIDING THE BONDING OF LEUKOCYTES TO FIBRINOGENS
JP2003503015A (ja) 1999-05-03 2003-01-28 メダレツクス・インコーポレーテツド スタフィロコッカス・アウレウスに対するヒト抗体
EP1181052A4 (en) * 1999-05-15 2004-08-11 Univ California San Diego AREAS WITH INTENDED ACTIVITIES BASED ON PROTEIN A
WO2001034809A2 (en) 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
EP1196193B1 (en) 1999-12-03 2008-11-05 Celltech Chiroscience Limited Interleukin-1 mutein useful as vaccine adjuvant
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
AU2001256958A1 (en) 2000-03-17 2001-10-03 Inhibitex, Inc. Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use
KR20020097200A (ko) 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 원핵세포에서의 필수유전자의 동정
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
SE0003573D0 (sv) * 2000-10-04 2000-10-04 Bengt Guss Method and means for producing novel von Willebrand factor binding proteins and their use in biotechnology
ATE317267T1 (de) 2000-11-07 2006-02-15 Immunovaccine Technologies Inc Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
CA2446294A1 (en) 2001-05-08 2002-11-14 Yi Xu Surface proteins from gram-positive bacteria having highly conserved motifs and antibodies that recognize them
CN100359327C (zh) 2001-06-15 2008-01-02 英希比泰克斯公司 识别凝血酶阴性的葡萄球菌和金黄色葡萄球菌的表面蛋白的交叉反应性单克隆抗体和多克隆抗体
CA2351018A1 (en) 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
JP4404627B2 (ja) 2001-08-02 2010-01-27 ユニヴァーシティー オヴ シェフィールド 抗原性ポリペプチド
US20030113350A1 (en) 2001-09-19 2003-06-19 Fattom Ali I. Glycoconjugate vaccines for use in immune-compromised populations
US7115264B2 (en) 2001-11-05 2006-10-03 Inhibitex Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections
WO2003041726A1 (en) 2001-11-16 2003-05-22 Biostapro Ab Use of an extracellular adherence protein for the manufacture of an anti-inflammatory drug
US7157443B2 (en) 2001-12-11 2007-01-02 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
WO2003076470A1 (en) 2002-03-05 2003-09-18 Inhibitex, Inc. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
US7736652B2 (en) 2002-03-21 2010-06-15 The Regents Of The University Of California Antibody fusion proteins: effective adjuvants of protein vaccination
US6984381B2 (en) 2002-07-05 2006-01-10 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for the prevention of bacterial infection of the bovine mammary gland
EP1540559B1 (en) 2002-09-13 2013-02-27 The Texas A & M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
WO2004030699A1 (en) 2002-10-03 2004-04-15 Intercell Ag Use of molecules which interact with the haptoglobin receptor ligand binding
JP5814494B2 (ja) 2002-11-12 2015-11-17 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. Staphylococcus感染に対する多糖類ワクチン
EP1583517B1 (en) 2002-11-12 2019-06-12 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
AU2003284643A1 (en) * 2002-11-22 2004-06-18 Daiichi Pure Chemicals Co., Ltd. Method of examining staphylococcus aureus
WO2004087759A2 (en) 2003-03-28 2004-10-14 Elusys Therapeutics, Inc. Method and compositions for conversion of antibody activity
EP1613642A4 (en) 2003-04-16 2008-07-02 Texas A & M Univ Sys EFB PROTEIN OF STAPHYLOCOCCUS AUREUS AND C3 BINDING STAGE THAT INHIBITS COMPLEMENTAL ACTIVATION
AU2004258979B2 (en) 2003-07-24 2007-12-06 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
US20080160089A1 (en) * 2003-10-14 2008-07-03 Medivas, Llc Vaccine delivery compositions and methods of use
JP2007528217A (ja) 2004-02-18 2007-10-11 メルク エンド カムパニー インコーポレーテッド スタヒロコッカス・アウレウスに対する防御免疫応答を誘導するためのポリペプチド
US20080095792A1 (en) 2004-09-17 2008-04-24 Anderson Annaliesa S Polypeptides For Inducing A Protective Immune Response Against Staphylococcus Aureus
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
CA2581746A1 (en) 2004-10-25 2006-06-08 The University Of Western Ontario Staphylococcus aureus isd protein-based anti-infectives
EP1814918A1 (en) 2004-10-29 2007-08-08 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
US20060134141A1 (en) 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
DK1838341T3 (da) 2005-01-20 2013-11-04 Isconova Ab Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
US20060228368A1 (en) 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US8398991B2 (en) 2005-06-22 2013-03-19 Institut Pasteur Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US20090317421A1 (en) 2006-01-18 2009-12-24 Dominique Missiakas Compositions and methods related to staphylococcal bacterium proteins
EP1982185A4 (en) 2006-01-27 2010-04-28 Merck Sharp & Dohme ON S. AUREUS ORF0657N OBJECTIVE ANTIGEN-BINDING PROTEINS
WO2007095057A2 (en) 2006-02-10 2007-08-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of eap protein for treating and preventing autoimmune neuroinflammatory diseases
EP1996231A4 (en) 2006-02-22 2010-09-15 Texas A & M Univ Sys ANTIBODIES WITH STRONG EXPRESSED PUTATIVE ANTIGEN DETECTION OF CA-MRSA AND METHOD OF USE
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
US20100021503A1 (en) 2006-03-30 2010-01-28 Glaxosmithkline Biologicals S.A. Immunogenic composition
TW200744632A (en) 2006-06-12 2007-12-16 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
WO2008140487A2 (en) 2006-11-14 2008-11-20 Elusys Therapeutics, Inc. Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use
US7488807B2 (en) 2006-11-22 2009-02-10 3M Innovative Properties Company Antibody with protein A selectivity
US20100047252A1 (en) 2006-11-22 2010-02-25 3M Innovative Properties Company Antibody with protein a selectivity
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US20100166772A1 (en) 2007-05-31 2010-07-01 Anderson Annaliesa S ANTIGEN-BINDING PROTEINS TARGETING S. AUREUS ORF0657n
EP2291196A4 (en) 2008-05-12 2012-05-30 Strox Biopharmaceuticals Llc FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
WO2010075548A2 (en) 2008-12-23 2010-07-01 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
CN102612523B (zh) 2009-04-03 2016-01-20 芝加哥大学 与蛋白a(spa)变体相关的组合物和方法
SG176837A1 (en) 2009-06-22 2012-01-30 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives
EP2555794A4 (en) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
KR20130093084A (ko) * 2010-07-02 2013-08-21 더 유니버시티 오브 시카고 단백질 A(SpA) 변이체와 관련된 조성물 및 방법

Also Published As

Publication number Publication date
PL2414387T3 (pl) 2016-06-30
EP2414387A2 (en) 2012-02-08
HRP20200727T1 (hr) 2020-07-24
JP2012522808A (ja) 2012-09-27
HUE026855T2 (hu) 2016-07-28
JP5789250B2 (ja) 2015-10-07
SMT201600033B (it) 2016-02-25
EP3281947B1 (en) 2020-02-12
CA2757543A1 (en) 2011-01-13
HK1162533A1 (zh) 2012-08-31
EP2414387A4 (en) 2012-08-15
BRPI1010307A2 (pt) 2016-03-22
AU2010271116B2 (en) 2015-08-13
AU2010271116A1 (en) 2011-10-27
EP3281947A1 (en) 2018-02-14
PT3281947T (pt) 2020-05-07
SI3281947T1 (sl) 2020-07-31
SI2414387T1 (sl) 2016-01-29
ES2563646T3 (es) 2016-03-15
SMT202000246T1 (it) 2020-07-08
CN102612523B (zh) 2016-01-20
PL3281947T3 (pl) 2020-07-27
CA2757543C (en) 2021-07-20
LT3281947T (lt) 2020-05-25
WO2011005341A3 (en) 2011-06-09
KR101773368B1 (ko) 2017-08-31
EP2414387B1 (en) 2015-12-16
HRP20160274T1 (hr) 2016-04-08
CY1123052T1 (el) 2021-10-29
KR20170102039A (ko) 2017-09-06
ZA201107702B (en) 2012-07-25
SG174968A1 (en) 2011-11-28
PT2414387E (pt) 2016-03-31
ES2784957T3 (es) 2020-10-02
KR20110138397A (ko) 2011-12-27
US20120114686A1 (en) 2012-05-10
DK3281947T3 (da) 2020-05-11
BRPI1010307B1 (pt) 2021-07-27
EP3002293A1 (en) 2016-04-06
DK2414387T3 (en) 2016-03-07
CN102612523A (zh) 2012-07-25
WO2011005341A2 (en) 2011-01-13
US9567379B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
HUE057713T2 (hu) A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek
EP2406399A4 (en) MIRAC PROTEINS
HUE040119T2 (hu) Orálisan alkalmazott kortikoszteroid készítmények
EP2588120A4 (en) COMPOSITIONS AND METHODS RELATED TO PROTEIN-A (SPA) VARIATIONS
SMT201700095B (is) Composizioni farmaceutiche per inalazione
DK3097925T3 (da) Farmaceutisk sammensætning
EP2442747A4 (en) DENTAL BRACES
BRPI1005289A8 (pt) cabeça de cimentar
EP2427572A4 (en) SEQUENCING METHODS
CR10571A (es) Vacuna virica recombinante
ATE450271T1 (de) Impfstoff
BRPI1004940A2 (pt) composição farmacêutica
DK3311828T3 (da) Modificerede vasoaktive tarmpeptider
DK2114993T3 (da) Vaccine
BRPI1015939A2 (pt) composição farmacêutica
BR112012004402A2 (pt) glicosilação de proteína
BRPI0922653A2 (pt) preparação farmacêutica
DE102009055987A8 (de) Spinell-Optokeramiken
BRPI1010661A2 (pt) peptídeo
BR112012003149A2 (pt) composição farmacêutica
ZA201109283B (en) Protein
DK2281524T3 (da) Tandstolpe
IT1395137B1 (it) Nuovi peptidi antipatogeni
EP2516702A4 (en) HIGHLIGHTING PROTEINS
ES1070798Y (es) Ataud